Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval of Trodelvy for bladder cancer therapeutics market

 

According to the study of the American Society of Clinical Oncology (ASCO), urothelial carcinoma accounts for around 90%, squamous cell carcinoma accounts for 4%, and adenocarcinoma accounts for 2% of all bladder cancer. The remaining 4% of bladder cancer includes other rare types of bladder cancer viz. sarcoma and small cell anaplastic cancer. Thus, the bladder cancer therapeutics market is experiencing strong growth on the account of the growing prevalence of bladder cancer. As per stats released by the International Agency for Research on Cancer (IARC), 59% of bladder cancer cases are observed in developed countries, with Belgium reporting the highest number of bladder cancer cases. Moreover, continuous advancements in clinical research have resulted in the development of new and advanced therapies for bladder cancer which is further projected to augment the growth of the market.

In April 2021, Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval of Trodelvy® (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1)

In April 2018, Roche announced that Tecentriq has been approved in India for two types of cancersnon-small cell lung cancer (NSCLC) and urothelial carcinoma, a type of bladder and urinary tract cancer

In June 2020, EMD Serono, the biopharmaceutical business of Merck KGaA and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.

North America is projected to witness strong growth in the global bladder cancer therapeutics market owing to increasing FDA approval for the launch of new and advanced bladder cancer therapies. For instance, in December 2019, the U.S. Food and Drug Administration granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in this case, the cell adhesion molecule Nectin-4, which is highly expressed in urothelial cancers.

Bladder cancer occurs when normal bladder tissue grows abnormally and invades other organs. Bladder cancer can be either primary or secondary. The first stage of bladder cancer occurs on the outside of the bladder, while the second stage occurs on the inside of the bladder. Bladder cancer therapeutics includes bladder liquid laser ablation, cryosurgery, perineal laser ablation, radical prostatectomy, perianal laser ablation, proton beam radiation therapy, selective laser radiotherapy, transrectal ultrasound therapy, transurethral resection, and transurethral resection. Staging is done according to the incidence and function of the disease.